CARRA is very excited to be participating in the Arthritis Foundation’s Walk to Cure Arthritis events around the country and we encourage you to join one of our existing teams or start your own!
CARRA’s mission is to conduct collaborative research to prevent, treat, and cure pediatric rheumatic diseases. We envision a world free of limitations from pediatric rheumatic diseases.
The goals of CARRA are to better understand all pediatric-onset rheumatic diseases; how to treat each and every patient most effectively and safely, and eventually find a cure. Learn more
The CARRA Registry collects disease and patient-reported information on thousands of children, adolescents and young adults with pediatric-onset rheumatic diseases in order to understand the characteristics of patients and course of each disorder, the biology and long-term effects of diseases and medications, as well as the effectiveness and safety of the medications being used to treat them. Learn more
CARRA embraces the voice of the patient in all their work. Partnering with patients and their families ensures research will address the questions that are most important to those most impacted. Pediatric rheumatic diseases include JIA (Juvenile Idiopathic Arthritis), pediatric lupus, juvenile dermatomyositis, vasculitis, scleroderma, and autoinflammatory diseases, among others.
The Arthritis Foundation has been a steadfast supporter of CARRA since its inception and is a major partner in support of our research to improve outcomes for children with rheumatic diseases.
The CARRA Newsletter is a bi-monthly, electronic newsletter published by CARRA for its members and other stakeholders. Each issue includes information about the organization, including upcoming events, activities, calls for submissions, and updates on the work of CARRA. It also publishes updates from other organizations and news from our members.
The CARRA Registry Newsletter is a quarterly publication for patients, families, and caregivers.
"We joined the CARRA Registry because we want to learn about the long term safety of the medications we use. We had so many questions after we received our diagnosis and felt the best way to answer those questions was with lots of data."